-
Je něco špatně v tomto záznamu ?
Synergism between WLBU2 peptide and antibiotics against methicillin-resistant Staphylococcus aureus and extended-spectrum beta-lactamase-producing Enterobacter cloacae
Lina Elsalem, Suhaila Al Sheboul, Ayat Khasawneh
Jazyk angličtina Země Česko
Typ dokumentu práce podpořená grantem
- MeSH
- bakteriální léková rezistence MeSH
- Enterobacter cloacae * účinky léků MeSH
- kationické antimikrobiální peptidy farmakologie terapeutické užití MeSH
- kombinovaná farmakoterapie MeSH
- lidé MeSH
- Staphylococcus aureus * účinky léků MeSH
- synergismus léků * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- práce podpořená grantem MeSH
Infections caused by Methicillin-Resistant Staphylococcus aureus (MRSA) and Extended-Spectrum Beta-Lactamase (ESBL) producing Enterobacter cloacae are considered as major therapeutic challenge due to their multidrug-resistant (MDR) phenotype against conventional antibiotics. WLBU2 is an engineered cationic peptide with potent antimicrobial activity. This in-vitro study aimed to evaluate the effects of WLBU2 against clinical isolates of the aforementioned bacteria and assess whether synergistic effects can be achieved upon combination with conventional antibiotics. The minimum inhibitory concentrations (MICs) of antimicrobial agents against bacterial clinical isolates (n = 30/strain) were determined using the microbroth dilution assay. The minimum bactericidal concentrations (MBCs) of WLBU2 were determined from microbroth dilution (MICs) tests by subculturing to agar plates. MICs of WLBU2 were evaluated in the presence of physiological concentrations of salts including NaCl, CaCl2 and MgCl2. To identify bacterial resistance profile, MRSA were treated with Oxacillin, Erythromycin and Vancomycin, while Ceftazidime, Ceftriaxone, Ciprofloxacin and Imipenem were used against Enterobacter cloacae. Combination treatments of antibiotics and sub-inhibitory concentrations of WLBU2 were conducted when MICs indicated intermediate/resistant susceptibility. The MICs/MBCs of WLBU2 were identical for each respective bacteria with values of 0.78-6.25 μM and 1.5-12.5 μM against MRSA and Enterobacter cloacae, respectively. WLBU2 was found as salt resistant. Combination treatment showed that synergistic and additive effects were achieved in many isolates of MRSA and Enterobacter cloacae. Our data revealed that WLBU2 is a potent peptide with bactericidal activity. In addition, it demonstrated the selective advantage of WLBU2 as a potential therapeutic agent under physiological solutions. Our findings also support the combination of WLBU2 and conventional antibiotics with potential application for treatment of resistant bacteria.
Citace poskytuje Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21013744
- 003
- CZ-PrNML
- 005
- 20210924153916.0
- 007
- ta
- 008
- 210502s2021 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.32725/jab.2021.001 $2 doi
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Elsalem, Lina $u Jordan University of Science and Technology, Faculty of Medicine, Department of Pharmacology, Irbid, Jordan
- 245 10
- $a Synergism between WLBU2 peptide and antibiotics against methicillin-resistant Staphylococcus aureus and extended-spectrum beta-lactamase-producing Enterobacter cloacae / $c Lina Elsalem, Suhaila Al Sheboul, Ayat Khasawneh
- 504 __
- $a Literatura
- 520 9_
- $a Infections caused by Methicillin-Resistant Staphylococcus aureus (MRSA) and Extended-Spectrum Beta-Lactamase (ESBL) producing Enterobacter cloacae are considered as major therapeutic challenge due to their multidrug-resistant (MDR) phenotype against conventional antibiotics. WLBU2 is an engineered cationic peptide with potent antimicrobial activity. This in-vitro study aimed to evaluate the effects of WLBU2 against clinical isolates of the aforementioned bacteria and assess whether synergistic effects can be achieved upon combination with conventional antibiotics. The minimum inhibitory concentrations (MICs) of antimicrobial agents against bacterial clinical isolates (n = 30/strain) were determined using the microbroth dilution assay. The minimum bactericidal concentrations (MBCs) of WLBU2 were determined from microbroth dilution (MICs) tests by subculturing to agar plates. MICs of WLBU2 were evaluated in the presence of physiological concentrations of salts including NaCl, CaCl2 and MgCl2. To identify bacterial resistance profile, MRSA were treated with Oxacillin, Erythromycin and Vancomycin, while Ceftazidime, Ceftriaxone, Ciprofloxacin and Imipenem were used against Enterobacter cloacae. Combination treatments of antibiotics and sub-inhibitory concentrations of WLBU2 were conducted when MICs indicated intermediate/resistant susceptibility. The MICs/MBCs of WLBU2 were identical for each respective bacteria with values of 0.78-6.25 μM and 1.5-12.5 μM against MRSA and Enterobacter cloacae, respectively. WLBU2 was found as salt resistant. Combination treatment showed that synergistic and additive effects were achieved in many isolates of MRSA and Enterobacter cloacae. Our data revealed that WLBU2 is a potent peptide with bactericidal activity. In addition, it demonstrated the selective advantage of WLBU2 as a potential therapeutic agent under physiological solutions. Our findings also support the combination of WLBU2 and conventional antibiotics with potential application for treatment of resistant bacteria.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a bakteriální léková rezistence $7 D024881
- 650 12
- $a Staphylococcus aureus $x účinky léků $7 D013211
- 650 12
- $a Enterobacter cloacae $x účinky léků $7 D016972
- 650 _2
- $a kationické antimikrobiální peptidy $x farmakologie $x terapeutické užití $7 D023181
- 650 12
- $a synergismus léků $7 D004357
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Al Sheboul, Suhaila $u Jordan University of Science and Technology, Faculty of Applied Medical Sciences, Department of Medical Laboratory Sciences, Irbid, Jordan
- 700 1_
- $a Khasawneh, Ayat $u ordan University of Science and Technology, Faculty of Medicine, Department of Pharmacology, Irbid, Jordan; The Jordanian Royal Medical Services, Department of Clinical Pathology and Microbiology, Amman, Jordan
- 773 0_
- $t Journal of applied biomedicine $x 1214-021X $g Roč. 19, č. 1 (2021), s. 14-25 $w MED00012667
- 910 __
- $a ABA008 $b B 2301 $c 1249 $y p $z 0
- 990 __
- $a 20210502154258 $b ABA008
- 991 __
- $a 20210924153914 $b ABA008
- 999 __
- $a ok $b bmc $g 1647901 $s 1134131
- BAS __
- $a 3
- BMC __
- $a 2021 $b 19 $c 1 $d 14-25 $i 1214-021X $m Journal of Applied Biomedicine $x MED00012667
- LZP __
- $c NLK109 $d 20210924 $a NLK 2021-20/dk